Pulse Biosciences (PLSE) said Thursday that preliminary data from its first-in-human study of nanosecond pulsed field ablation technology showed reduction in benign thyroid nodule sizes by over 50% on average.
The pulses did not leave any residual fibrosis or scarring and symptoms improved within the first month, according to the company.
The company's shares fell 3% in recent trading.
Price: 17.18, Change: -0.54, Percent Change: -3.08
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.